Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane

O'Shaughnessy J, Schwartzberg L, Piccart M, Rugo HS, Yardley DA, Cortes J, Untch M, Harbeck N, Wright GS, Bondarenko I, Glaspy J, Nowecki Z, Kayali F, Chan A, Levy C, Liu MC, Kim SB, Lemieux J, Manikhas A, Tolaney S, Lim E, Gombos A, Stradella A, Pegram M, Fasching P, Mangel L, Semiglazov V, Dieras V, Gianni L, Danso MA, Vacirca J, Kroll S, O'Connell J, Tang K, Wei T, Seidman A (2021)

Publication Type: Conference contribution

Publication year: 2021

Journal

Publisher: AMER ASSOC CANCER RESEARCH

City/Town: PHILADELPHIA

Conference Proceedings Title: CANCER RESEARCH

DOI: 10.1158/1538-7445.sabcs20-gs4-01

Authors with CRIS profile

Involved external institutions

Université Laval (UL) Canada (CA) Maria Skłodowska-Curie Institute of Oncology / Centrum Onkologii–Instytut im. Marii Skłodowskiej-Curie w Warszawie Poland (PL) Dana–Farber Cancer Institute United States (USA) (US) Odonate Therapeutics Inc United States (USA) (US) The US Oncology Network United States (USA) (US) Memorial Sloan Kettering Cancer Center United States (USA) (US) Université libre de Bruxelles (ULB) / Free University of Brussels Belgium (BE) Quirónsalud Spain (ES) Breast Cancer Research Centre-Western Australia Australia (AU) University of California San Francisco (UCSF) United States (USA) (US) West Cancer Center United States (USA) (US) Baylor University (BU) United States (USA) (US) Sarah Cannon Research Institute (SCRI) United States (USA) (US) Sarah Cannon Research Institute United Kingdom United Kingdom (GB) University of Pécs / Pécsi Tudományegyetem Hungary (HU) Center François Baclesse France (FR) Ludwig-Maximilians-Universität (LMU) Germany (DE) Ospedale San Raffaele (früher: Centro San Raffaele del Monte Tabor Foundation) Italy (IT) Centre Eugène Marquis France (FR) Dnipropetrovsk Regional Clinical Hospital Ukraine (UA) Petrov Research Institute of Oncology / НИИ Онкологии им. Петрова Russian Federation (RU) Koo Foundation Sun Yat-Sen Cancer Center Taiwan (TW) Stanford Medicine United States (USA) (US) Duran i Reynals Hospital Spain (ES) National Cancer Centre Singapore (NCCS) Singapore (SG) University of Ulsan / 울산대학교 Korea, Republic of (KR) HELIOS Kliniken Germany (DE)

How to cite

APA:

O'Shaughnessy, J., Schwartzberg, L., Piccart, M., Rugo, H.S., Yardley, D.A., Cortes, J.,... Seidman, A. (2021). Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane. In CANCER RESEARCH. PHILADELPHIA: AMER ASSOC CANCER RESEARCH.

MLA:

O'Shaughnessy, Joyce, et al. "Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor plus (HR plus ) metastatic breast cancer (MBC) who have previously received a taxane." Proceedings of the CANCER RESEARCH PHILADELPHIA: AMER ASSOC CANCER RESEARCH, 2021.

BibTeX: Download